Treatment with high-dose estrogen (diethylstilbestrol) significantly decreases plasma estrogen and androgen levels but does not influence in vivo aromatization in postmenopausal breast cancer patients

Geisler, Jürgen; Haynes, Ben P.; Anker, Gun; Helle, Hildegunn; Ekse, Dagfinn; Dowsett, Mitch; Lønning, Per Eystein

doi:10.1016/j.jsbmb.2005.05.004

Cited by 16 publications

(13 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To this day, she remains disease-free 10 years and six months after commencing DES treatment. In search for alternative endocrine mechanisms explaining this observation, we found DES to decrease plasma androgen and estrogen concentrations but to have no influence on in vivo aromatization [93] probably indicating an effect on adrenal steroid secretion. Yet, it is unlikely these endocrine effects may be of significant importance to the anti-tumour effect observed.…”

Section: Estrogens As Additive Treatment In Breast Cancermentioning

confidence: 82%

Additive endocrine therapy for advanced breast cancer – back to the future

Lønning

2009

Acta Oncologica

Self Cite

View full text Add to dashboard Cite

While novel endocrine treatment options have been implemented in the advanced - as well as adjuvant setting, recent results suggest a place for "old-fashioned" additive treatment with estrogens in advanced breast cancer. This paper reviews the biological rationale for endocrine therapy in general and additive treatment with estrogens in particular. The finding that patients becoming resistant to treatment with aromatase inhibitors may subsequently respond to estrogen therapy adds important information to our understanding of therapy resistance in general. Moreover, the return of a therapeutic option abandoned more than 20 years ago, now to be used in a different sequential setting, suggests a critical examination whether there may be other conventional treatment options still earning a place as treatment in advanced disease as well. While ablative therapies including surgical oophorectomy, hypophysectomy and adrenalectomy are not candidate treatment options due to morbidity, there are additive treatment options apart from estrogen therapy that may be considered. Androgens administered at therapeutic doses are not feasible for toxicity reasons; yet, the potential of adding androgens in small doses as adjuvant to aromatase inhibitors should be further explored. Whether patients become resistant to other treatment options may still benefit from megestrol acetate, remains to be explored.

show abstract

Section: Estrogens As Additive Treatment In Breast Cancermentioning

confidence: 82%

Additive endocrine therapy for advanced breast cancer – back to the future

Lønning

2009

Acta Oncologica

Self Cite

View full text Add to dashboard Cite

show abstract

“…Moreover, hormonal therapeutics have been used for decades as anticancer medications, contraceptives, hormone replacement, and fertility drugs (28)(29)(30)(31)(32)(33). Thus, a wide range of clinical conditions require frequent monitoring of these hormones in tissue or blood for accurate diagnosis and treatment.…”

Section: Discussionmentioning

confidence: 99%

Droplet-Scale Estrogen Assays in Breast Tissue, Blood, and Serum

et al. 2009

View full text Add to dashboard Cite

Estrogen is a key hormone in human reproductive physiology, controlling ovulation and secondary sexual characteristics. In addition, it plays an important role in the pathogenesis of breast cancer. Indeed, estrogen receptor antagonists and aromatase inhibitors (which block estrogen biosynthesis) are primary drugs used for treatment and prevention in at-risk populations. Despite its importance, tissue concentrations of estrogen are not routinely measured because conventional techniques require large samples of biopsies for analysis. In response to this need, we have developed a digital microfluidic method and applied it to the extraction and quantification of estrogen in 1-microliter samples of breast tissue homogenate (as would be collected with fine-needle aspiration), as well as in whole blood and serum. This method may be broadly applicable to conditions requiring frequent analysis of hormones in clinical samples (for example, infertility and cancer).

show abstract

“…The anticancer role of oestrogen could also be mediated through its antiangiogenic effects by inhibiting the growth and migration of vascular smooth muscle cells [44]. Finally, it has been demonstrated that DES may very effectively inhibit enzymes of androgen steroidogenesis in adrenal and tumour tissues to suppress local tissue androgen levels [45][46][47][48] (Table II).…”

Section: Mechanism Of Actionmentioning

confidence: 99%

“…Daehlin et al [45], Geisler et al [46], Guo et al [47], Magoffin and Erickson [48] oestrogens through a transdermal patch has been proposed.…”

Section: Mechanism Of Action Studiesmentioning

confidence: 99%

Diethylstilboestrol for the treatment of prostate cancer: past, present and future

Turo¹,

Smolski²,

Esler³

et al. 2013

Scandinavian Journal of Urology

View full text Add to dashboard Cite

The aim of this review was to discuss the most recent data from current trials of diethylstilboestrol (DES) to identify its present role in advanced prostate cancer treatment as new hormonal therapies emerge. The most relevant clinical studies using DES in castration-refractory prostate cancer (CRPC) were identified from the literature. The safety, efficacy, outcomes and mechanisms of action are summarized. In the age of chemotherapy this review highlights the efficacy of oestrogen therapy in CRPC. The optimal point in the therapeutic pathway at which DES should be prescribed remains to be established.

show abstract

Treatment with high-dose estrogen (diethylstilbestrol) significantly decreases plasma estrogen and androgen levels but does not influence in vivo aromatization in postmenopausal breast cancer patients

Cited by 16 publications

References 44 publications

Additive endocrine therapy for advanced breast cancer – back to the future

Additive endocrine therapy for advanced breast cancer – back to the future

Droplet-Scale Estrogen Assays in Breast Tissue, Blood, and Serum

Diethylstilboestrol for the treatment of prostate cancer: past, present and future

Contact Info

Product

Resources

About